Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1175911

Phenotype switching in melanoma cells resistant to targeted therapy


Radić, Martina; Tadijan, Ana; Jazvinšćak Jembrek, Maja; Vlašić, Ignacija; Ozretić, Petar; Herak Bosnar, Maja; Slade, Neda
Phenotype switching in melanoma cells resistant to targeted therapy // 45th FEBS Congress, Molecules of Life: Towards New Horizons
Ljubljana, Slovenija (Virtual), 2021. (predavanje, međunarodna recenzija, neobjavljeni rad, znanstveni)


CROSBI ID: 1175911 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Phenotype switching in melanoma cells resistant to targeted therapy

Autori
Radić, Martina ; Tadijan, Ana ; Jazvinšćak Jembrek, Maja ; Vlašić, Ignacija ; Ozretić, Petar ; Herak Bosnar, Maja ; Slade, Neda

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, neobjavljeni rad, znanstveni

Skup
45th FEBS Congress, Molecules of Life: Towards New Horizons

Mjesto i datum
Ljubljana, Slovenija (Virtual), 03-08.07.2021

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Melanoma ; targeted therapy resistance ; phenotype switching

Sažetak
Melanoma is an aggressive malignancy that is, despite being a rare type of cancer, responsible for the vast majority of skin cancer­related deaths. Recent advances in melanoma therapy, like targeted therapy and immunotherapy, contributed profoundly to the increased overall survival of patients. Nevertheless, the development of resistance to therapy remains a major clinical issue. Targeted therapy, like the BRAF inhibitor (BRAFi) therapy for melanoma patients harboring the V600E mutation, is initially highly effective, but the majority of patients develop resistance and relapse within a few months. To better understand the mechanisms of resistance to the BRAFi targeted therapy, we generated cell lines resistant to vemurafenib, a BRAF inhibitor used for the treatment of late­stage melanoma with the common BRAFV600E mutation. Vemurafenib­ resistant human melanoma cell lines were generated by growing primary melanoma, WM793B cell line, and metastatic melanoma, A375M cell line, both harboring the BRAFV600E mutation, in the vemurafenib­ enriched medium. The occurrence of resistance was confirmed by the MTT assay. Newly generated resistant cell lines showed immense phenotype changes in terms of cell migration and proliferation. Our results indicated partial EM transition, which is known to increase invasive cell properties, promoting resistance to anti­cancer drugs. We performed mass­ based parallel cell mRNA sequencing (RNA­seq) and found that the mechanism of resistance differs between the two cell lines. Furthermore, we have demonstrated a significant downregulation of metastasis suppressor genes, NME1 and NME2, and the p53 protein isoform Δ133p53β, which was shown to promote cancer cell invasion. A number of previous studies suggested several mechanisms of resistance and phenotype switching in targeted therapy. Our results set a new direction for further research in therapy resistance that needs to be elucidated.

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Temeljne medicinske znanosti



POVEZANOST RADA


Projekti:
IP-2013-11-1615 - Otkrivanje novih proteinskih interakcija kao podloga za nove pristupe liječenju melanoma čovjeka (ProNetMel) (Slade, Neda, HRZZ - 2013-11) ( POIROT)

Ustanove:
Institut "Ruđer Bošković", Zagreb

Poveznice na cjeloviti tekst rada:

2021.febscongress.org 2021.febscongress.org

Citiraj ovu publikaciju:

Radić, Martina; Tadijan, Ana; Jazvinšćak Jembrek, Maja; Vlašić, Ignacija; Ozretić, Petar; Herak Bosnar, Maja; Slade, Neda
Phenotype switching in melanoma cells resistant to targeted therapy // 45th FEBS Congress, Molecules of Life: Towards New Horizons
Ljubljana, Slovenija (Virtual), 2021. (predavanje, međunarodna recenzija, neobjavljeni rad, znanstveni)
Radić, M., Tadijan, A., Jazvinšćak Jembrek, M., Vlašić, I., Ozretić, P., Herak Bosnar, M. & Slade, N. (2021) Phenotype switching in melanoma cells resistant to targeted therapy. U: 45th FEBS Congress, Molecules of Life: Towards New Horizons.
@article{article, author = {Radi\'{c}, Martina and Tadijan, Ana and Jazvin\v{s}\'{c}ak Jembrek, Maja and Vla\v{s}i\'{c}, Ignacija and Ozreti\'{c}, Petar and Herak Bosnar, Maja and Slade, Neda}, year = {2021}, keywords = {Melanoma, targeted therapy resistance, phenotype switching}, title = {Phenotype switching in melanoma cells resistant to targeted therapy}, keyword = {Melanoma, targeted therapy resistance, phenotype switching}, publisherplace = {Ljubljana, Slovenija (Virtual)} }
@article{article, author = {Radi\'{c}, Martina and Tadijan, Ana and Jazvin\v{s}\'{c}ak Jembrek, Maja and Vla\v{s}i\'{c}, Ignacija and Ozreti\'{c}, Petar and Herak Bosnar, Maja and Slade, Neda}, year = {2021}, keywords = {Melanoma, targeted therapy resistance, phenotype switching}, title = {Phenotype switching in melanoma cells resistant to targeted therapy}, keyword = {Melanoma, targeted therapy resistance, phenotype switching}, publisherplace = {Ljubljana, Slovenija (Virtual)} }




Contrast
Increase Font
Decrease Font
Dyslexic Font